Sensitivity marker for antibody-drug conjugate
US12312641B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 22, 2019 |
| Grant date | May 27, 2025 |
| Priority date | — |
| Expiry date | Jul 28, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2030/8827
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method for identifying a subject to whom a medicament containing an anti-hTROP2 antibody is to be given, wherein the subject is a human patient suffering from a cancer, comprising: obtaining a biological sample from the human patient diagnosed as suffering from a cancer; evaluating an amount of expression of the hTROP2 gene at mRNA level in the biological sample; evaluating an amount of expression of the SLFN11 gene at mRNA level in the biological sample, wherein the biological sample is one that is determined to have a high amount of expression of the hTROP2 gene; and identifying the human patient who provided the biological sample, wherein the biological sample is one that is determined to have a high amount of expression of the SLFN11 gene, as a subject to whom a medicament containing an anti-hTROP2 antibody is to be given.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.